Coadministration of oral cyclosporin A enables oral therapy with paclitaxel

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3379-3384

  Meerum Terwogt, Jetske M ^a   Malingré, Mirte M ^a   Beijnen, Jos H ^a,b   Ten Bokkel Huinink, Wim W ^a   Rosing, Hilde ^a   Koopman, Franciska J ^a   Van Tellingen, Olaf ^a   Swart, Martha ^a   Schellens, Jan H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CREMOPHOR; CYCLOSPORIN A; DRUG METABOLITE; GLYCOPROTEIN P; PACLITAXEL;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; GRANULOCYTOPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CYCLOSPORINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL;

EID: 0001583660     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V., ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., and Beijnen, J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol., 11: 2117-2135, 1993.
2. Huizing, M. T., Sewberath Misser, V. H., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H., Vermorken, J. B., Pinedo, H. M., and Beijnen, J. H. Taxanes: a new class of antitumor agents. Cancer Invest., 13: 381-404, 1995.
3. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
4. Weiss, R. B. Hypersensitivity reactions. Semin. Oncol., 19: 458-477, 1992.
5. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
6. Nannan Panday, V. R., Huizing, M. T., ten Bokkel Huinink, W. W., Vermorken, J. B., and Beijnen, J. H. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin. Drug Invest., 14: 418-427, 1997.
7. Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., and Doenicke, A. Histamine release in dogs by Cremophor EL and its derivatives. Agents Actions, 7: 63-67, 1977.
8. Dorr, R. T. Pharmacology and toxicology of cremophor EL diluent. Ann. Pharmacother., 28: S11-S14, 1994.
9. Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res., 56: 2112-2115, 1996.
10. van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., and Beijnen J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer, 76: 1181-1183. 1997.
11. Fujita, H., Okamota, M., Takao, A., Mase, H., and Kojima, H. Pharmacokinetics of paclitaxel in experimental animals. Part I. Blood level (Japanese). Kan to Kagaku Ryoho, 21: 653-658, 1994.
12. 1 mice. Cancer Chemother. Pharmacol., 34: 465-471, 1994.
13. Dano, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta, 323: 466-483, 1973.
14. Inaba, M., and Sakuri, Y. Enhanced efflux of actinomycin D, vincristine and vinblastine in Adriamycin-resistant subline of P388 leukemia. Cancer Lett., 8: 111-115, 1979.
15. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., Berns, A. J., and Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994.
16. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
17. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamad, M. R., and Bertino, J. R. Multi drug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA, 86: 695-698, 1989.
18. Borst, P., and Schinkel, A. H. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet., 13: 217-222, 1997.
19. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 4: 2031-2035, 1997.
20. Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Determination of paclitaxel and metabolites in mouse plasma, tissue, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 664: 383-391, 1995.
21. Huizing, M. T., Sparreboom, A., Rosing, H., van Tellingen, O., Pinedo, H. M., and Beijnen, J. H. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 674: 261-268, 1995.
22. Gibaldi, M., and Perrier, D. Noncompartmental analysis based on statistical moment theory. In: M. Gibaldi, and D. Perrier, (eds.), Pharmacokinetics, Ed. 2, pp. 409-417. New York: Dekker, 1982.
23. Huizing, M. T., Giaccone, G., Van Warmerdam, L. J. C., Rosing, H., Bakker, P. J., Vermorken, J. B., Postmus, P. E., van Zandwijk, N., Koolen, M. G., ten Bokkel Huinink, W. W., van der Vijgh, W. J., Bierhorst, F. J., Lai, A., Dalesio, O., Pinedo, H. M., Veenhof, C. H., and Beijnen, J. H. Phannacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer. J. Clin. Oncol., 15: 317-329, 1997.
24. Sparreboom, A., van Tellingen, O., Huizing, M. T., Nooijen, W. J., and Beijnen, J. H. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by precolumn derivatization and reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 681: 355-362, 1996.
25. Chan, G. L., Weinstein, S. S., LeFor, W. W., Spoto, E., Kahana, L., and Shires, D. L. Relative performance of specific and nonspecific fluorescence immunoassay for cyclosporin in transplant patients. Ther. Drug Monit., 14: 42-47, 1992.
26. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J. Clin. Oncol., 13: 180-190, 1995.
27. Shet, M. S., Fisher, C. W., Holmans, P. L., and Estabrook, R. W. Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc. Natl. Acad. Sci. USA, 90: 11748-11752, 1993.
28. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P., and Collins, J. M. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.
29. Kivistö, K. T., Kroemer, H. K., and Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol., 40: 523-530, 1995.
30. Sparreboom, A., Huizing, M. T., Boesen, J. J. B., Nooijen, W. J., van Tellingen, O, and Beijnen, J. H. Isolation, purification and biological activity of mono-and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother. Pharmacol., 36: 299, 1995.
31. Olyaei, A. J., de Mattos, A. M., and Bennett, W. M. Schwitching between cyclosporin formulations-what are the risks? Drug Saf., 16: 366-373, 1997.
32. Arbuck, S. G., Strauss, H., Rowinsky, E., Christian, M., Suffness, M., Adams, J., Oakes, M., McGuire, W., Reed, E., Gibbs, H., Greenfield, R. A., and Montello, M. A reassessment of cardiac toxicity associated with Taxol. J. Natl. Cancer Inst. Monogr., 15: 117-130, 1993.
33. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J. and Roden, D. M. The drug transporter P-glycoprotein limits oral absorbtion and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101: 289-294, 1998.
34. Schinkel, A. H., Mol, C. A. A. M, Wagenaar, E., van Deemter, L., Smit, J. J., and Borst, P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer. 31A: 1295-1298, 1995.
35. Borst, P, and Schinkel, A. H. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur. J. Cancer, 32A: 985-990, 1996.